SJRET6: Protocol for the Study and Treatment of Participants with Intraocular Retinoblastoma


Phase I/II Studies : Retinoblastoma


Retinoblastoma is a rare cancer of the retina of the eye. Researchers at St. Jude want to find out if the response to treatment can be improved by giving chemotherapy directly to the eye with the first 2 cycles of treatment in children with retinoblastoma who have one or both eyes with advanced tumors. Researchers also want to learn more about the genetics and biology of retinoblastoma, and how these tumors develop (called tumorigenesis). To achieve this goal, we will study tumor samples from children who take part in this study, when part of their treatment requires enucleation (removal of the eye). Many children with retinoblastoma will not have an eye removed and will not take part in the biology research, but they can still receive treatment on this study.


Eligibility Criteria, among others, include:

For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).


Rachel Brennan, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-888-226-4343 or 901-595-4055
FAX: 901-595-4011

Referring or consulting physicians only:

For all other inquiries about St. Jude Children's Research Hospital studies:

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.